CTNM
HealthcareContineum Therapeutics, Inc.
$10.00
$-1.39 (-12.20%)
Jan 5, 2026
Price History (1Y)
Analysis
Contineum Therapeutics, Inc. is a biotechnology company within the healthcare sector with a market capitalization of $365.29M. It operates on an industry scale with 41 employees. The company's financial health indicates negative profitability, as evidenced by gross margin, operating margin, and profit margin all at 0.0%. Returns on equity and assets are also in the red, with -30.4% and -20.9%, respectively. The balance sheet shows a significant amount of cash, $182.41M, against relatively low debt, $5.49M, resulting in a debt-to-equity ratio of 3.04. The valuation context is characterized by a negative forward P/E of -4.46 and an EV/EBITDA of -2.30. The company's cash position of $182.41M represents a substantial amount relative to its market capitalization.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $365.29M
- P/E Ratio
- N/A
- 52-Week High
- $14.90
- 52-Week Low
- $3.35
- Avg Volume
- 181.88K
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 41